XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.26.1

Selected balance sheet information | 3 Months Ended
--- | ---
Mar. 31, 2026
Selected balance sheet information |
Selected balance sheet information |
3. | Selected balance sheet information
Inventory consists of the following at: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | March 31, | ​ ​ ​ | December 31,
(in thousands) | ​ | 2026 | ​ | 2025
Raw material | ​ | $ | 8,413 | ​ | $ | 8,628
Work-in-process | ​ |  | 623 | ​ |  | 473
Finished goods | ​ |  | 3,367 | ​ |  | 3,104
​ | ​ | $ | 12,403 | ​ | $ | 12,205
​ Property and equipment, net consists of the following at: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | March 31, | ​ ​ ​ | December 31,
(in thousands) | ​ | 2026 | ​ | 2025
Office furniture and equipment | ​ | $ | 399 | ​ | $ | 512
Lab equipment | ​ |  | 2,679 | ​ |  | 3,533
Computer equipment and software | ​ |  | 962 | ​ |  | 1,194
Leasehold improvements | ​ |  | 828 | ​ |  | 827
Capital equipment in process | ​ |  | 374 | ​ |  | 325
​ | ​ |  | 5,242 | ​ |  | 6,391
Less: Accumulated depreciation and amortization | ​ |  | 3,083 | ​ |  | 4,148
​ | ​ | $ | 2,159 | ​ | $ | 2,243
​ Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation expense was $0.2 for each of the three months ended March 31, 2026 and 2025, respectively. ​ Accrued expenses consist of the following at: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | March 31, | ​ ​ ​ | December 31,
(in thousands) | ​ | 2026 | ​ | 2025
Bonuses | ​ | $ | 2,792 | ​ | $ | 5,200
Accrued interest payable | ​ | ​ | 479 | ​ | ​ | 403
Paid time off | ​ | ​ | 472 | ​ | ​ | 630
401(k) match | ​ | ​ | 418 | ​ | ​ | 1,136
Operating lease liability, current portion | ​ | ​ | 361 | ​ | ​ | 352
Customer rebates | ​ | ​ | 313 | ​ | ​ | 801
Employee stock purchase plan | ​ | ​ | 262 | ​ | ​ | 116
Taxes | ​ | ​ | 127 | ​ | ​ | 93
Clinical trial and other professional fees | ​ | ​ | 98 | ​ | ​ | 116
Other | ​ |  | 1,166 | ​ |  | 637
​ | ​ | $ | 6,488 | ​ | $ | 9,484
​

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration